Progress in structure and function of DNA topoisomerase I and anticancer camptothecin drugs

Chinese Pharmaceutical Journal

Volumn 37, Issue 9, 2002, Pages 646-650

  Song, Yun long ^a   Zhang, Wan nian ^a   Ji, Hai tao ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME STRUCTURE; SEQUENCE HOMOLOGY;

EID: 0036709809     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wang JC. DNA topoisomerases [J]. Annu Rev Biochem, 1996,65:635.
2. Nitiss JL. Investigating the biological functions of DNA topoisomerases in eukaryotic cells [J]. Biochim Biophys Acta, 1998, 1400(1-3):63.
3. Wallis JW, Chrebet G, Brodsky G, et al. A hyper-recombination mutation in S. cererisiae identifies a novel eukaryotic topoisomerases [J]. Cell, 1989,58(2):409.
4. Hanai R, Caron PR, Wang JC. Human TOP3: A single copy gene encoding DNA topoisomerase III [J]. Proc Natl Acad Sci USA, 1996,93(8):3653.
5. Berger JM, Fass D, Wang JC, et al. Structural' similarities between topoisomerase that cleave one or both DNA strands [J]. Proc Natl Acad Sci USA, 1998,95(14):7876.
6. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerase I [J]. Biochim Biophys Acta, 1995,1262(1):1.
7. Yu L, Zhu CX, Tse-Dinh YC, et al. Solution structure of the Cterminal single-stranded DNA binding domain of Escherichia coli topoisomerase I [J]. Biochemistry, 1995,34(23):7622.
8. Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA[J]. Science, 1998,279(5356):1504.
9. Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomerase I [J]. Science, 1998,279(5356): 1534.
10. Cheng C, Kussie P, Pavletich N, et al. Conservation of structure and mechanism between eukaryotic topoisomerase I and sitespecific recombinases [J]. Cell, 1998,92(6):841.
11. Stewart L, Ireton GC, Parker LH, et al. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I [J]. J Biol Chem, 1996,271(13):7593.
12. Alsner J, Svejstrup JQ, Kjeldsen E, et al. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function [J]. J Biol Chem, 1992,267(18):12408.
13. Redinbo MR, Stewart L, Champoux JJ, et al. Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures [J]. J Mol Biol, 1999,292:685.
14. Redinbo MR, Champoux JJ, Hol WG. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA [J]. Biochemistry, 2000,39(23):6832.
15. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins [J]. Biochim Biophys Acta, 1998,1400(1-3): 107.
16. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata [J]. J Am Chem Soc, 1966,88:3888.
17. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin [J]. Cancer Res, 1988,48(7):1722.
18. Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase [J]. Cancer Res, 2000,60(15):4206.
19. Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV 40 DNA replication system [J]. Cancer Res, 1993,53(24):5908.
20. Jaxel C,Capranico G,Kerrigan D, et al. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin [J]. J Biol Chem, 1991,266(30):20418.
21. Pommier Y, Kohlhagen G, Kohn KW, et al. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage site [J]. Proc Natl Acad Sci USA, 1995,92(19):8861.
22. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity [J]. J Med Chem, 1991,34 (1):98.
23. Sawada S, Nokata K, Furuta T, et al. Chemical modification of an antitumor alkaloid camptothecin synthesis and antitumor activity of 7-C-substituted camptothecins [J]. Chem Pharm Bull Tokyo, 1991,39(10):2574.
24. Emerson DL, Besterman JM, Brown HR, et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues [J]. Cancer Res, 1995,55(3):603.
25. Redinbo MR, Champoux JJ, Hol WG. Structural insights into the function of type I B topoisomerases [J]. Curr Opin Struct Biol, 1999,9:29.
26. Fan Y, Weinstein JN, Kohn KW, et al. Molecular modelling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin [J]. J Med Chem, 1998,41(13):2216.
27. Wang XY, Zhou X, Hecht SM, et al. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I -DNA binary complex [J]. Biochemistry, 1999,38(14):4374.
28. Lavergne O, Lesueur-Ginot L, Pla Rodas F, et al. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues [J]. J Med Chem, 1998,41(27): 5410.
29. Lavergne O, Demarquay D, Bailly C, et al. Topoisomerase I -mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins [J]. J Med Chem, 2000,43(11):2285.
30. Pollack IF, Erff M, Born D, et al. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo [J]. Cancer Res, 1999,59(19):4898.